All News
Half the Experts are Wrong (2.17.2023)
Dr. Jack Cush reviews the news and tries to stump the expert panel this week on the podcast.
Read Article
New Laboratory Insights for the ANA+ Consult
A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).
Read Article
Older Lupus Patients Need Follow-Up After Hospital Discharge
MedPage Today
Medicare beneficiaries 65 and older with lupus faced dramatically higher mortality when they received no follow-up care during the month after a hospital stay, researchers found.
Read Article
Deucravacitinib - Effective in Systemic Lupus Erythematosus
A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active systemic lupus erythematosus (SLE).
Read Article
Toxic Epiderman Necrolysis vs Acute Cutaneous Lupus Erythematosus
https://t.co/wKX3v01RUb https://t.co/SWwnH7ph04
Links:
Dr. John Cush RheumNow ( View Tweet)
Steroids assisting options - CTX, LEF or RTX @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/gVw2tGKYNG https://t.co/ItIKB8MFTI
Links:
Dr. John Cush RheumNow ( View Tweet)
Case reports of anifrolumab use in 2 pts w/ chronic, scarring discoid lupus unresponsive to steriods, HCQ, immunosuppressants & CTX. Case 1 SLEDAI from 13 to 2 in 24 weeks & CLASI-A from 26 to 3 in 20wks. Cs 2 CLASI-A decr 24 to 5 after 1 infusion https://t.co/Qe2rF4Avxe
Links:
Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib - Effective in Systemic Lupus Erythematosus
A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active SLE.
https://t.co/YS8n02BEsk https://t.co/4sBd88AhtK
Links:
Dr. John Cush RheumNow ( View Tweet)
Have you heard of nipocalimab? It prevents IgG-FcRn by binding to the FcRn IgG binding site. This is one to watch in our diseases (RA, Sjogren’s, SLE, myopathies.) Dr. Postolova #RWCS23 @RheumNow @RWCSmtg https://t.co/qMGA6IdtUE
Dr. Rachel Tate uptoTate ( View Tweet)
Older Lupus Patients Need Follow-Up After Hospital Discharge
Medicare beneficiaries 65 and older with lupus faced dramatically higher mortality when they received no follow-up care during the month after a hospital stay, researchers found.
https://t.co/4mFctXGQH9 https://t.co/2Q1z03myud
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 232 pediatric #SLE pts. Over 12 mos 47% achieved LLDAS & Damage seen in 40% after 6.2 yrs F/U. Getting to LLDAS w/in 12 mos is assoc w less damage. LLDAS w/in 12 mos more likely in Absence of renal involvement. https://t.co/pGethJCw4e https://t.co/eYpVueIKbf
Links:
Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib - Effective in Systemic Lupus Erythematosus
A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active SLE.
https://t.co/0g2VM6TJt6 https://t.co/f6wylPc5ep
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort study of Taiwan Health Insurance Database looked at risk of #SLE in pts w/ Hashimoto’s thyroiditis (HT). Compared 15K HTvs 31K controls. SLE was incr in HT pts (IRR 3.58; p < 0.01). Several sensitivity analyses aHR 4.35 to 5.11 https://t.co/QaWEN4Chw9 https://t.co/bD8zrCJEXY
Links:
Dr. John Cush RheumNow ( View Tweet)
NLRP12 is a negative regulator of innate immune activation and type I interferon production. SLE PBMCs have low levels NLRP12 (inverse correl w/ IFNa & Hi Dz activity. NLRP12 knockouts or deficiency Incr autoAbs, inflammation & renal damage https://t.co/VICAqKmK9r https://t.co/MxqcNzh6BQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Meta-analysis (21 studies, 3948 pregnant pts) HCQ may reduce risk of preeclampsia (OR 0.45) & premature delivery (OR 0.84) in pregnant autoimmune pts. HCQ may also reduce risk of gestational HTN (OR 0.42) & pre-term birth (OR 0.63) in pregnant SLE pts https://t.co/riQDRN9r1A https://t.co/uR8Nem4Ndx
Links:
Dr. John Cush RheumNow ( View Tweet)
NLRP12 is a negative regulator of innate immune activation and type I interferon production. SLE PBMCs have low levels NLRP12 (inverse correl w/ IFNa & Hi Dz activity. NLRP12 knockouts or deficiency Incr autoAbs, inflammation & renal damage https://t.co/PjTQNHhduB https://t.co/m0erNXMkUC
Links:
Dr. John Cush RheumNow ( View Tweet)
New Guideline: Vaccinations OK With Few Tweaks for Rheum Patients
Nearly all available vaccines can be given to people with rheumatologic diseases, according to a new, detailed guideline from the ACR.
https://t.co/514mIylgzj https://t.co/9Zq9pGcujV
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA has approved the 1st BTK (Bruton’s tyrosine kinase) inhibitor (Jaypirca™ or pirtobrutinib) for adults with refractory mantle cell lymphoma. BTK inhibitors are also being developed for use in MS, RA, SLE, pemphigus & more https://t.co/599tK21H1Z https://t.co/KSqMMDWmfd
Links:
Dr. John Cush RheumNow ( View Tweet)
Feb 3rd, today is #NationalWomenPhysiciansDay. The date honors Dr. Elizabeth Blackwell, 1st woman to receive an MD United States (1849). RheumNow will devote the whole month of April 2023 to our Campaign on Women in Rheumatology - stay tuned! https://t.co/l1M56L8h9N https://t.co/eQpetW02CE
Links:
Dr. John Cush RheumNow ( View Tweet)
Pathogenic Impact of microRNA Cotargeting in Lupus
A group of researchers from the Graduate School of Medicine at Nagoya University in Japan have discovered the impact of microRNA (miRNA) on inflammation in lupus in mice.
https://t.co/j0TRgIaam6 https://t.co/HNJbsTfT7c
Links:
Dr. John Cush RheumNow ( View Tweet)
